Objective: De novo mutations of SCN8A, encoding the voltage-gated sodium channel Na V 1.6, have been associated with a severe infant onset epileptic encephalopathy. Individuals with SCN8A encephalopathy have a mean age of seizure onset of 4-5 months, with multiple seizure types that are often refractory to treatment with available drugs. Anecdotal reports suggest that high-dose phenytoin is effective for some patients, but there are associated adverse effects and potential for toxicity. Functional characterization of several SCN8A encephalopathy variants has shown that elevated persistent sodium current is one of several common biophysical defects. Therefore, specifically targeting elevated persistent current may be a useful therapeutic strategy in some cases. Methods: The novel sodium channel modulator GS967 has greater preference for persistent as opposed to peak current and nearly 10-fold greater potency than phenytoin. We evaluated the therapeutic effect of GS967 in the Scn8a N1768D/+ mouse model carrying an SCN8A patient mutation that results in elevated persistent sodium current. We also performed patch clamp recordings to assess the effect of GS967 on peak and persistent sodium current and excitability in hippocampal neurons from Scn8a N1768D/+ mice.
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Results: GS967 potently blocked persistent sodium current without affecting peak current, normalized action potential morphology, and attenuated excitability in neurons from heterozygous Scn8a N1768D/+ mice. Acute treatment with GS967 provided dose-dependent protection against maximal electroshock-induced seizures in Scn8a N1768D/+ and wild-type mice. Chronic treatment of Scn8a N1768D/+ mice with GS967 resulted in lower seizure burden and complete protection from seizure-associated lethality observed in untreated Scn8a N1768D/+ mice. Protection was achieved at a chronic dose that did not cause overt behavioral toxicity or sedation.
Significance: Persistent sodium current modulators like GS967 may be an effective precision targeting strategy for SCN8A encephalopathy and other functionally similar channelopathies when elevated persistent sodium current is the primary dysfunction.
| INTRODUCTION
Epilepsy is a common neurological disorder, with a lifetime incidence of 1 in 26. 1 Mutations in genes encoding neuronal voltage-gated sodium channels have been implicated in several types of human epilepsy, including epileptic encephalopathies. 2 These are severe epilepsies with cooccurring cognitive, behavioral, and neurological deficits due to the combined effect of seizure activity and the underlying mutation. 3 In recent years, >150 cases of epileptic encephalopathy have been associated with de novo mutations in SCN8A, encoding the Na V 1.6 voltage-gated sodium channel pore-forming (alpha) subunit. The clinical phenotype begins in the first year of life with pleiomorphic seizures that are difficult to control, delayed cognitive development, and motor impairment. 4 SCN8A encephalopathy is also associated with an elevated risk for sudden unexpected death in epilepsy (SUDEP), making seizure control a high priority. 5, 6 The first report of SCN8A encephalopathy described a female proband with multiple seizure types, intellectual disability, developmental delay, and motor impairment.
2 She succumbed to SUDEP at 15 years of age. Whole genome sequencing of the family quartet identified the heterozygous, de novo mutation SCN8A p.Asn1768Asp (N1768D). 7 Electrophysiologic recording of sodium currents in ND7/23 cells expressing the mutant channel revealed a large persistent sodium current as the primary biophysical defect, as well as incomplete channel inactivation and a shift in the voltage dependence of steady-state fast inactivation. 7 Introduction of the N1768D mutation into the murine Scn8a gene resulted in a mouse model that recapitulates many features of the human syndrome. 8, 9 Specifically, heterozygous Scn8a Several types of biophysical defects have been documented for variants associated with SCN8A encephalopathy. Targeting persistent sodium current, one of the common primary biophysical defects in this disorder, may provide an effective precision therapeutic approach. Reports have described patients achieving seizure control with carbamazepine, oxcarbazepine, valproic acid, and most notably, high-dose phenytoin. [11] [12] [13] [14] [15] [16] Phenytoin is a statedependent sodium channel blocker with a small preference (~10%) for persistent current over peak current. 17 However, high-dose phenytoin has significant safety concerns due to saturable metabolism and risk for phenytoin poisoning. [18] [19] [20] [21] GS-458967 (GS967) is a novel sodium channel modulator specifically developed to inhibit persistent sodium current, with a 42-fold preference for persistent as opposed to peak current inhibition. 22 Our previous studies demonstrated that acute application of GS967 to hippocampal neurons did not affect the current-voltage relationship or voltage dependence of activation, but induced a hyperpolarized shift of steady-state channel inactivation and slowed both recovery from fast inactivation and onset of slow inactivation.
23
GS967 has also been reported to have strong use-dependent block.
24
GS967 was previously tested in the Scn2a Q54 mouse model with epilepsy caused by elevated persistent sodium current in hippocampal neurons. 25 In the current study, we tested the effect of GS967 on persistent sodium current and action potential firing in neurons, as well as seizure susceptibility, spontaneous seizures, and survival of Scn8a D/+ mice. We report that GS967 suppresses persistent sodium current and excitability in neurons ex vivo, and protects against seizures and premature lethality in vivo, supporting targeting of persistent sodium current as a potential therapeutic strategy for this disorder.
Key Points
• GS967 potently suppressed persistent sodium current in acutely dissociated neurons and hyperexcitability in slices from heterozygous Scn8a Previous studies showed that chronic treatment with this dose resulted in GS967 plasma and brain concentrations of 1.0 AE 0.08 and 1.7 AE 0.1 lmolÁL -1 , respectively. 23 Chronic treatment with GS967 at 1.5 mg/kg/d did not cause overt adverse neurobehavioral or sedating effects in WT C3HeB/FeJ at 5-7 weeks of treatment ( Figure S1 ).
| Isolated neuron preparation and electrophysiologic recording
Neurons were acutely isolated from untreated Scn8a following offline digital subtraction, as previously described. 26, 27 Persistent current was measured utilizing a 200-millisecond depolarizing step. Mean current in the final 10 milliseconds was normalized to peak transient current. Statistical comparisons were made using Student's t test or 1-way analysis of variance (ANOVA) followed by Tukey post hoc test, and P < .05 was considered statistically significant.
| Brain slice preparation and electrophysiologic recording
Brain slices were prepared from WT and Scn8a D/+ mice (>8 weeks of age) using a Leica Microsystems (Wetzlar, Germany) VT1200 vibratome as previously described.
10
CA1 pyramidal neurons were visually identified using infrared video microscopy (Hamamatsu Photonics, Hamamatsu, Japan) with a Zeiss (Oberkochen, Germany) Axioscope microscope. Whole-cell current clamp recordings were performed as previously described. 10 During recordings, slices were held in a small chamber and superfused with oxygenated artificial cerebrospinal fluid (in mmolÁL -1 :
125 NaCl, 2. Action potentials (APs) were evoked using a depolarizing current injection step of 400 pA. To standardize across neurons, resting membrane potentials were maintained at À70 mV by injection of direct current. Only depolarizing events that consisted of a single observable peak initiating from threshold and had an upstroke velocity > 150 mV/ms were considered as APs. Early afterdepolarizations (EADs) were identified as spikelets that occurred during the repolarizing phases of the initial AP and had slower upstroke velocities (>15 mV/ms), longer widths, and depolarized thresholds. Input resistance was calculated using a À20-pA hyperpolarizing current injection step. The approximate rheobase for each cell was defined as the highest current injection step that did not evoke any APs. AP duration (APD) was defined as the width of the AP at the halfway voltage between threshold and AP peak and was measured for the first AP elicited during a 400-pA current injection. To measure intrinsic membrane and AP properties, a ramp of depolarizing current (0-400 pA) was injected into each neuron over a 4-second time period. Threshold was identified as the membrane potential at which the upstroke velocity was 5% of its maximum. 28 AP amplitude, upstroke velocity, and downstroke velocity were calculated using the first evoked AP during the current ramp. Amplitude was defined as the difference between threshold and AP peak, whereas upstroke velocity and downstroke velocity were defined as the maximum and minimum slope of the evoked AP, respectively.
| MES
At 4 weeks of age, mice were assigned to treatment groups by block randomization and received an intraperitoneal injection of test compound (phenytoin or GS967) or its respective vehicle in a volume of 10 mL/kg body weight 2 hours prior to testing. MES tests were conducted at the previously determined time to peak effect for GS967 and phenytoin. 25 Corneal electroshock was delivered using a pulse generator set at a frequency of 60 Hz and 0.5-millisecond pulse width (Ugo Basile, Varese, Italy) with shock duration = 0.2 second and current = 20 mA (120 mC) for Scn8a D/+ and 0.4 second, 60 mA (720 mC) for WT mice. Mice were scored for the presence or absence of full tonic hindlimb extension (hindlimbs at a 180°angle to torso) occurring within 5 seconds of the shock. ED 50 values were determined from doseresponse curves generated and compared with Prism software (GraphPad Software, La Jolla, CA, USA). mice, persistent current was equal to 1.7 AE 0.3% of peak current (n = 8; Figure 1A , black trace). The magnitude of persistent current is lower than previous reports due to differences in cell type and recording conditions. 10 To assess the ability of either GS967 or phenytoin to selectively inhibit persistent sodium current, neurons were acutely treated with drug concentrations approximating the therapeutic free drug concentration in mouse brain, 200 nmolÁL -1 GS967 or 4 lmolÁL -1 phenytoin. In the presence of GS967, persistent current was >10-fold lower than in the absence of compound (0.12 AE 0.06% of peak current, n = 7; P < .001, 1-way ANOVA and Tukey post hoc). In the presence of phenytoin, persistent current was approximately 2-fold lower than in drug-free conditions (0.94 AE 0.09% of peak current, n = 6; P < .04). Thus, GS967 was more potent than phenytoin in suppressing persistent current mediated by the mutant channel (P < .04; Figure 1A ,B). Importantly, neither compound significantly altered peak sodium current under these conditions ( Figure 1C ).
| Survival
assay, mice underwent a training trial (4 rpm) and then 3 test trials with acceleration from 4 to 40 rpm over 5 min (
| GS967 suppresses EADs and reduces
neuronal excitability in CA1 pyramidal neurons from Scn8a D/+ mice AP waveforms from Scn8a D/+ mouse CA1 pyramidal neurons exhibited prominent EADs that were evident during the repolarization phase of APs (Figure 2A -C), in agreement with previous studies. 30 These abnormal waveforms were not observed in WT controls ( Figure 2D ). Addition of GS967 had a profound effect on EADs, reducing their number by 41% at 500 nmolÁL -1 and 50% at 1 lmolÁL -1 GS967 (Fig- ure 2B,C). GS967 had no effect on AP firing frequencies from either Scn8a D/+ or WT (+/+) neurons (Figure 2Ai -Di).
Analysis of AP parameters revealed differences between Scn8a D/+ and WT neurons (Table S1 ). GS967 (1 lmolÁL -1 )
decreased AP amplitude and upstroke velocity in both Scn8a D/+ and WT neurons. AP thresholds were also depolarized in Scn8a D/+ neurons, but not WT ( Figure 2E , Table S1 ).
APDs were not changed (Table S1 ). These findings demonstrate that GS967 can modulate intrinsic hyperexcitability of CA1 neurons from Scn8a D/+ mice.
| GS967 is more potent than phenytoin for seizure protection in the MES assay
We assessed acute anticonvulsant activity of GS967 and phenytoin using the MES paradigm in Scn8a D/+ mice and F I G U R E 1 GS967 inhibits persistent sodium current in acutely isolated hippocampal pyramidal neurons from Scn8a D/+ mice.
A, Representative traces showing persistent sodium current of untreated (black), GS967-treated (red), and phenytoin (Phen)-treated (blue) neurons from Scn8a D/+ mice. B,C, Summary data of persistent sodium current (B) and current-voltage relationship for peak sodium current (C) for untreated (black symbols, n = 8), phenytoin-treated (blue symbols, n = 6), and GS967-treated (red symbols, n = 7) neurons from Scn8a D/+ mice.
Open symbols represent individual cells, whereas closed symbols represent mean AE standard error of the mean. Statistical comparison was performed using 1-way analysis of variance followed by Tukey's post hoc test. *Statistically significant difference compared to untreated cells for phenytoin-treated (P < .04) and GS967-treated (P < .001) cells
WT littermates. The electroconvulsive stimulus (ECS) required to induce maximal hindlimb extension in >95% of mice (ECS 95 ) was determined for both genotypes. Scn8a D/+ mice required a stimulus of 120 mC compared to 720 mC for WT mice. Varying doses of GS967 or phenytoin were administered 2 hours prior to MES induction using the genotype-appropriate ECS 95 . Both GS967 and phenytoin provided dose-dependent protection against MES-induced tonic hindlimb seizures, with GS967 exhibiting greater potency. Scn8a D/+ mice were protected from maximal hindlimb extension with a calculated ED 50 of 1.2 AE 0.2 mg/kg for GS967 and 5.3 AE 0.7 mg/kg for phenytoin ( Figure 3A) . Similar results were found in WT mice with an ED 50 of 0.7 AE 0.2 mg/kg for GS967 and 6.9 AE 0.5 mg/kg for phenytoin ( Figure 3B ).
| Chronic GS967 treatment prolongs survival of Scn8a D/+ mice
Survival of Scn8a D/+ mice is limited, with <50% of mice surviving to 6 months of age. 9 To determine whether chronic treatment with GS967 would extend survival, Scn8a D/+ mice were fed chow containing GS967 (estimated dose = 1.5 mg/kg/d) beginning at 6 weeks and continuing until 6 months of age. This dose was previously shown to be anticonvulsant in Scn2a Q54 and Scn1a +/À mouse models 23, 25 and does not produce any signs of behavioral toxicity or sedation ( Figure S1 ). Treatment with GS967 beginning at 6 weeks and continuing to 6 months of age completely rescued premature lethality of Scn8a D/+ mice, with 100% of GS967-treated mice (n = 32) surviving to 6 months of age, compared with only 24% of untreated mice (7/29; P < .001, Mantel-Cox log-rank). Removal of the GS967 chow at 6 months of age resulted in rapid loss of protection, and 65% of the previously treated mice died within the following 3 months ( Figure 4A ). Loss of GS967 benefit following withdrawal suggests that it acts primarily as an anticonvulsant rather than a disease-modifying treatment. feeding nursing dams GS967 beginning at P5, extended survival by 1 week (P < .001, Mantel-Cox log-rank; Figure 4B ). . Values are mean AE standard error of the mean. Significant results were determined using paired Student's t test with alpha set to .05. ns, nonsignificant. *P < .05, **P < .01
| GS967 reduces spontaneous seizures in

Scn8a
D/+ mice Previous reports showed that Scn8a D/+ mice have spontaneous seizures with onset at 2 to 4 months of age, followed by death within a few days of seizure onset. 9, 31 To evaluate the effect of GS967 on spontaneous seizures, mice were continuously observed with a combination of video-EEG monitoring and continuous video monitoring for several hundred hours ( Figure 5 ; Figure S2 ). Only 2 of 7 GS967-treated mice experienced any seizures during the time of monitoring, compared with 7 of 7 untreated mice (Table 1) . All recorded seizures in Scn8a D/+ mice initiated with a tonic phase and culminated in full tonic hindlimb extension, with the angle of hindlimbs to the torso ≥ 180°. Several of the untreated mice exhibited seizure clustering, with days of seizure freedom separating periods of high seizure frequency ( Figure S2 ). Untreated Scn8a D/+ mice also exhibited seizures with multiple tonic to tonic-clonic transitions. In contrast, seizures in the GS967-treated Scn8a D/+ mice had a single tonic phase that terminated with postictal suppression. Combined analysis of video-EEG and video monitoring showed that Scn8a D/+ mice treated with GS967 had significantly lower seizure frequency, with 0.3 AE 0.2 seizures/24 hours in GS967-treated compared with 1.6 AE 0.4 seizures/24 hours in untreated mice (P < .004, Figure 5C , Table 1 ). No seizures were observed in WT littermate mice (Table 1 ). These data demonstrate that GS967 has a potent antiseizure effect in a mouse model of SCN8A encephalopathy.
| DISCUSSION
In this study, we demonstrated that GS967 significantly reduced spontaneous seizure burden and improved survival in the Scn8a D/+ epilepsy model. We also demonstrated that GS967 provided protection from acute MES-induced seizures in both Scn8a D/+ and WT mice.
4.1 | GS967 is a potent blocker of persistent current arising from the Scn8a N1768D mutation
We and others previously reported that GS967 is a potent inhibitor of persistent sodium current, 22, 24, [32] [33] [34] with 9-fold greater potency than phenytoin in hippocampal pyramidal neurons from Scn2a Q54 mice. 25 Consistent with these reports, acute application of 200 nmolÁL -1 GS967 or 4 lmolÁL
phenytoin to acutely dissociated hippocampal neurons isolated from Scn8a D/+ mice resulted in inhibition of persistent sodium current without significantly affecting peak current. Similarly, acute application of GS967 to hippocampal slices from Scn8a D/+ mice resulted in normalization of intrinsic excitability in CA1 neurons.
| Anticonvulsant activity of GS967
To assess anticonvulsant activity of GS967, we first established the dose-response relationship of acutely administered GS967 for MES-induced seizures, using the The curve for GS967 is significantly shifted compared to phenytoin, and the estimated ED 50 for GS967 and phenytoin are 1.1 AE 0.23 and 5.33 AE 0.69 mg/kg, respectively (P < .001, n = 5-24, Student's t test). Symbols represent mean AE standard error of the mean. B, Doseresponse curves of GS967 and phenytoin for MES seizures in WT mice. The curve is also significantly shifted, and the estimated ED 50 for GS967 and phenytoin are 0.70 AE 0.22 and 6.93 AE 0.45 mg/kg, respectively (P < .001, n = 6-26, Student's t test)
conventional anticonvulsant phenytoin as a comparator. We demonstrated that GS967 provided dose-dependent protection against MES-induced seizures with~5-10-fold greater potency than phenytoin in both WT and Scn8a D/+ mice. Survival difference between treatment groups was significant (P < .001; n = 6-8; Mantel-Cox log-rank test). WT, wild-type Although we demonstrate dramatic improvement in seizure burden and survival in Scn8a D/+ mice treated with GS967, there are some limitations of our preclinical study that warrant consideration. First, GS967 treatment was commenced prior to seizure onset and it is not known whether commencing treatment after fulminant onset would provide the same level of protection. Second, the age of seizure onset in the mouse Scn8a D/+ model is later than that observed in the proband, suggesting that the mouse model does not directly phenocopy the human case. Third, SCN8A encephalopathy includes mutations that result in a variety of Na V 1.6 dysfunction ranging from gain-of-function defects, including but not limited to persistent sodium current, to loss-of-function defects. This suggests that GS967 would not necessarily be broadly effective in all cases of SCN8A encephalopathy, but rather that knowledge of the specific channel dysfunction may provide additional information for rational therapy choice. Beyond Scn8a D/+ mice, GS967 was previously shown to reduce seizure burden and improve survival in Scn2a Q54 mice, which share the biophysical defect of elevated persistent sodium current. 25, 37 GS967 was also shown to have a protective effect in the Scn1a +/À Dravet mouse model that has reduced activity in inhibitory neurons and elevated excitability in excitatory neurons in mice. 23, 26 However, there is no evidence for alteration of persistent current in this model, suggesting that GS967 can have protective benefit in a genetic model with an alternate underlying mechanism. Furthermore, we demonstrated here and in a previous report that GS967 has potent antiseizure activity in the MES assay in WT mice, 25 supporting potentially broader applicability of GS967 in epilepsies with divergent etiologies.
| CONCLUSIONS
We demonstrate that targeting of a specific biophysical defect in Na V 1.6 gating observed with some SCN8A patient mutations is an effective antiepileptic treatment strategy in Scn8a D/+ mice. This supports a precision medicine approach to SCN8A encephalopathy and suggests that defining the biophysical defect may provide valuable information to guide therapy. Moreover, results from acute MES studies and other genetic models suggest that suppression of Na V 1.6 activity may also be a general therapeutic approach relevant to other genetic and nongenetic epilepsies.
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